Form 4 filings across 2 companies. Net figures count open-market buys and sales only. EDGAR profile ↗
Lifetime net: -$363.3K
Reported holding is the most recent post-transaction share count on a Table I row.
How quickly this filer reports. Section 16 allows two business days from the transaction.
All 6 filings we hold were filed within the two-business-day deadline.
Counted in business days from the transaction date, or the deemed execution date where the filing reports one, excluding weekends and federal holidays. How this is measured · All late filings
The 22 most recent Form 4 transactions.
| Open the original filing on SEC.gov |
| Sep 11 | NBIX | Neurocrine Biosciences INC | AGRANT◷ | 5,020 | — | — | +11.7% | Open the original filing on SEC.gov |
| Jun 12 | FATE | Fate Therapeutics INC | AGRANT◆ | 87,900 | — | — | — | Open the original filing on SEC.gov |
| Mar 4 | NBIX | Neurocrine Biosciences INC | GGIFT | 2,249 | — | — | -5.0% | Open the original filing on SEC.gov |
| Feb 13 | NBIX | Neurocrine Biosciences INC | AGRANT◆ | 7,735 | — | — | — | Open the original filing on SEC.gov |
| Feb 13 | NBIX | Neurocrine Biosciences INC | AGRANT◆ | 44,095 | — | — | — | Open the original filing on SEC.gov |
| Feb 13 | NBIX | Neurocrine Biosciences INC | MEXER◆ | 2,566 | — | — | — | Open the original filing on SEC.gov |
| Feb 13 | NBIX | Neurocrine Biosciences INC | MEXER◆ | 2,241 | — | — | — | Open the original filing on SEC.gov |
| Feb 13 | NBIX | Neurocrine Biosciences INC | FTAX | 5,378 | $124.12 | $667.5K | -10.7% | Open the original filing on SEC.gov |
| Feb 13 | NBIX | Neurocrine Biosciences INC | AGRANT | 9,968 | — | — | +24.7% | Open the original filing on SEC.gov |
| Feb 13 | NBIX | Neurocrine Biosciences INC | FTAX | 1,385 | $124.12 | $171.9K | -3.3% | Open the original filing on SEC.gov |
| Feb 13 | NBIX | Neurocrine Biosciences INC | MEXER | 2,566 | — | — | +6.6% | Open the original filing on SEC.gov |
| Feb 13 | NBIX | Neurocrine Biosciences INC | FTAX | 1,210 | $124.12 | $150.2K | -3.0% | Open the original filing on SEC.gov |
| Feb 13 | NBIX | Neurocrine Biosciences INC | MEXER | 2,241 | — | — | +5.9% | Open the original filing on SEC.gov |
| Feb 12 | NBIX | Neurocrine Biosciences INC | MEXER◆ | 2,133 | — | — | — | Open the original filing on SEC.gov |
| Feb 12 | NBIX | Neurocrine Biosciences INC | FTAX | 1,151 | $123.10 | $141.7K | -2.9% | Open the original filing on SEC.gov |
| Feb 12 | NBIX | Neurocrine Biosciences INC | MEXER | 2,133 | — | — | +5.8% | Open the original filing on SEC.gov |
| Jan 31 | NBIX | Neurocrine Biosciences INC | MEXER◆ | 2,437 | — | — | — | Open the original filing on SEC.gov |
| Jan 31 | NBIX | Neurocrine Biosciences INC | FTAX | 1,368 | $136.06 | $186.1K | -3.6% | Open the original filing on SEC.gov |
| Jan 31 | NBIX | Neurocrine Biosciences INC | MEXER | 2,437 | — | — | +6.8% | Open the original filing on SEC.gov |
| May 29, 2025 | FATE | Fate Therapeutics INC | AGRANT◆ | 110,000 | — | — | — | Open the original filing on SEC.gov |